

RECEIVED
CENTRAL FAX CENTERFAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

SEP 07 2004

Applicants Docket Number:
DEA V2002/0045 US NPApplicants:
Stefanie Flohr, et alSerial No.
10/613,482Filing Date:
July 3, 2003Title of Invention:
PYRAZOLOISOQUINOLINE DERIVATIVES FOR
INHIBITING NFKAPPAB-INDUCING KINASE

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at (703) 872-2306, on

Date of Deposit September 7, 2004

Printed Name of Person Signing Certificate Maribel Mendez

Signature *Maribel Mendez*

Total Number of Pages Sent: 17

Attorney: Balaram Gupta

Group Art Unit: 1625
Examiner: Seaman, D. MargaretTO: Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Amendment Pursuant to 37 C.F.R.</u>
<u>§ 1.121 and Reply Pursuant to 37 C.F.R.</u>
<u>§ 1.111 (16 pgs.)</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

SEP 07 2004

PATENT

Docket No.: DEAV2002/0045 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Stefanie Flohr, et al.

Examiner: Seaman, D. Margaret

Serial No.: 10/613,482

Art Unit: 1625

Filed: July 3, 2003

TELEFAX CERTIFICATETitle: **Pyrazoloisoquinoline Derivatives for
Inhibiting NFKAPPAB-Inducing Kinase**I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at (703) 872-9306 on

Date of Transmission

Signature

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY
PURSUANT TO 37 C.F.R. § 1.111**

Sir:

This is a Rule 111 Amendment in the above-identified patent application in response to the Office Action, paper no. 20040601, dated, June 4, 2004, having a response due by, September 7, 2004. It is respectfully requested that the following amendments and remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 14.

DEAV2002/0045 US NP

-1 of 16-